|1.||Nishimoto, Norihiro: 33 articles (05/2015 - 05/2005)|
|2.||Kishimoto, Tadamitsu: 29 articles (01/2015 - 11/2006)|
|3.||Tanaka, Toshio: 27 articles (03/2015 - 12/2009)|
|4.||Yokota, Shumpei: 20 articles (04/2015 - 06/2005)|
|5.||Takeuchi, Tsutomu: 19 articles (10/2015 - 09/2007)|
|6.||Ogata, Atsushi: 18 articles (10/2015 - 12/2009)|
|7.||Ueki, Yukitaka: 13 articles (03/2015 - 04/2011)|
|8.||Mori, Masaaki: 13 articles (01/2015 - 06/2005)|
|9.||Tanaka, Yoshiya: 12 articles (05/2015 - 04/2011)|
|10.||Wendling, Daniel: 12 articles (04/2015 - 06/2010)|
06/01/2010 - "The previous clinical studies have demonstrated tocilizumab monotherapy to be highly effective in rheumatoid arthritis (RA). "
01/01/2015 - "Remarkable efficacy of tocilizumab for treating rheumatoid arthritis in patients with high platelet counts."
11/01/2013 - "To determine the optimal conditions for inducing rheumatoid arthritis (RA) into disease remission by tocilizumab (TCZ), we analyzed the TCZ therapy carried out in our facility. "
06/01/2015 - "Tocilizumab treatment results in significant improvement, maintained over time, of pcJIA signs and symptoms and has a safety profile consistent with that for adults with rheumatoid arthritis. "
02/01/2014 - "Tocilizumab, an anti-IL-6 receptor antibody, is effective in the treatment of various autoimmune and inflammatory conditions notably rheumatoid arthritis. "
|2.||Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis)
01/01/2015 - "Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis."
06/01/2014 - "Tocilizumab (TCZ), an antiinterleukin-6 receptor monoclonal antibody, is clinically beneficial in patients with systemic-onset juvenile idiopathic arthritis (sJIA). "
03/22/2008 - "Tocilizumab is effective in children with systemic-onset juvenile idiopathic arthritis. "
07/01/2014 - "The safety and efficacy of tocilizumab (TCZ), an anti-IL-6 receptor monoclonal antibody, have been reported in the treatment of children with systemic juvenile idiopathic arthritis (sJIA). "
02/01/2012 - "We evaluated the safety and efficacy of tocilizumab in polyarticular-course juvenile idiopathic arthritis (pJIA) with polyarticular or oligoarticular onset. "
|3.||Giant Lymph Node Hyperplasia (Castleman's Disease)
08/01/2012 - "Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody."
01/01/2007 - "This is the first report on tocilizumab efficacy for Castleman's disease after approval for use for Castleman's disease."
05/10/2007 - "[Effectiveness of humanized anti-interleukin-6 receptor antibody (tocilizumab) for Castleman's disease mainly with pulmonary involvement]."
04/01/2014 - "Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance."
01/01/2012 - "Tocilizumab treatment was significantly effective for uveitis accompanied with Castleman disease. "
01/01/2015 - "In published case reports, tocilizumab (TCZ) has shown good efficacy for AA amyloidosis in almost all patients. "
05/01/2014 - "In the present study, safety and efficacy of 1-year treatment with an anti-IL-6 receptor antibody tocilizumab (TCZ) on RA and AA amyloidosis were estimated. "
01/01/2015 - "AA amyloidosis treated with tocilizumab: case series and updated literature review."
01/01/2014 - "Therapeutic Benefits of Tocilizumab Vary in Different Organs of a Patient with AA Amyloidosis."
01/01/2013 - "Tocilizumab (TCZ) is a humanized anti-IL-6 receptor antibody that has emerged as an effective and specific treatment in AA amyloidosis secondary to chronic inflammatory disorders. "
06/01/2008 - "In conclusion, tocilizumab improved established arthritis in monkey and monkey CIA model is useful for the analysis of anti-arthritic effect of tocilizumab."
01/01/2014 - "Because of gradually worsening arthritis, tocilizumab was administered and arthritis improved markedly. "
09/01/2014 - "We report a 47-year-old woman with psoriastic arthritis who developed under anti-TNFα therapy and later under tocilizumab a paradoxical palmoplantar eruption. "
08/01/2008 - "Is tocilizumab an option for the treatment of arthritis?"
06/01/2008 - "RANKL showed overproduction with arthritis and suppressed with tocilizumab treatment. "
|1.||Interleukin-6 (Interleukin 6)
|3.||Interleukin-6 Receptors (Interleukin 6 Receptor)
|6.||Antirheumatic Agents (DMARD)
|8.||TNFR-Fc fusion protein (etanercept)
|9.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|2.||Drug Therapy (Chemotherapy)
|3.||Molecular Targeted Therapy